LiverTox Green Tea Extract DILI Audit
QA controls for EGCG, ALT signals and label risk
Last Updated: July 2026
LiverTox Green Tea Extract DILI Audit
Quick Answer: NIH LiverTox classifies green tea extract as a well-established cause of clinically apparent liver injury. QA teams should not treat green tea extract as a generic “natural antioxidant.” They should audit EGCG dose, caffeine, catechin profile, fasting-use directions, liver-warning language and batch records before release.
The NIH LiverTox green tea monograph separates brewed green tea from concentrated green tea extract. LiverTox states that drinking green tea has not been associated with liver injury, but green tea extract has been implicated in clinically apparent acute liver injury, including rare liver failure.
EGCG is the central catechin marker for this risk review. The PubChem EGCG record lists EGCG as C22H18O11, molecular weight 458.4 g/mol, and CAS 989-51-5. Blue Eye Biotech supports EGCG 98% sourcing with USP, EP, ISO and cGMP-style documentation in one supplier file.
What does NIH LiverTox say about green tea extract liver injury?
Answer: NIH LiverTox states that green tea extract is a likely recognized cause of clinically apparent liver injury. Reported cases usually show acute hepatitis-like symptoms, marked ALT and AST elevation, a hepatocellular pattern, latency commonly within 1–6 months, and improvement after stopping the extract.
LiverTox gives green tea extract a Likelihood Score A, meaning “well established cause of clinically apparent liver injury.” That classification is a QA signal. It does not mean every batch is unsafe. It means supplier review must quantify dose and exposure conditions.
| LiverTox signal | Reported pattern | QA translation |
|---|---|---|
| Likelihood score | A: well established cause of liver injury | Escalate EGCG formula to safety and regulatory review |
| Typical latency | Usually 1–6 months after starting product | Monitor complaint timing and repeat-purchase exposure |
| Lab pattern | Marked hepatocellular ALT/AST elevation | Treat ALT/AST reports as serious complaint triggers |
| Clinical course | Often improves after stopping extract | Add stop-use and adverse event escalation workflow |
| Rechallenge | Faster recurrence reported in some cases | Warn against re-use after suspected liver injury |
“The majority of cases present with an acute hepatitis-like syndrome and a markedly hepatocellular pattern of serum enzyme elevations.” NIH NIDDK, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, updated 2020. NIH LiverTox green tea monograph.
Which LiverTox case details matter most for supplement brands?
Answer: The most useful LiverTox case details are dose form, green tea extract amount, ALT, AST, bilirubin, alkaline phosphatase, latency, reexposure and recovery after stopping. These details help brands distinguish a general consumer complaint from a possible drug-induced liver injury signal.
LiverTox case examples show high ALT values, jaundice and hepatocellular patterns. The cases also show the attribution problem common in supplements: many products contain multiple botanicals, caffeine sources and weight-loss ingredients. That is why green tea extract specifications must be quantitative.
| Audit field | Example from LiverTox-style review | Brand action |
|---|---|---|
| Latency | 4–5 weeks to several months in case examples | Track first-use date in adverse event forms |
| ALT and AST | Marked aminotransferase elevation in hepatocellular pattern | Escalate any consumer report with lab values |
| Bilirubin | Jaundice reported in severe cases | Treat jaundice, dark urine and abdominal pain as serious signals |
| Reexposure | Recurrence with shorter latency in some case reports | Advise no rechallenge after suspected injury |
| Multi-ingredient formula | Weight-loss products often contain several botanicals and caffeine sources | Calculate total EGCG and total caffeine across all sources |
The DILIN catechin analysis by Navarro et al. found catechins in 49 of 97 supplement products implicated in hepatotoxicity, and 29 of 73 products without labeled green tea extract or catechins still contained detectable catechins. This makes hidden catechin testing a real QA issue.
How should QA convert LiverTox into an EGCG specification?
Answer: QA should convert LiverTox into a specification by quantifying EGCG per serving, EGCG per day, total catechins, caffeine, residual solvents, pesticides, heavy metals, microbiology and dosage form. A “green tea extract” ingredient line is not enough for DILI risk control.
The specification must support the actual consumer exposure. One capsule, two gummies or one scoop can deliver very different EGCG doses. A supplier COA should therefore report actual EGCG and caffeine, not only “polyphenols.”
| Specification item | Minimum evidence | Why LiverTox makes it important |
|---|---|---|
| EGCG assay | HPLC result, calculation basis and chromatogram | EGCG is the main catechin implicated in risk discussions |
| Total catechins | EGCG, ECG, EGC, EC and GCG profile | Catechin profile varies with manufacturing process |
| Caffeine | Batch-specific caffeine result by HPLC | Caffeine affects stimulant risk and consumer directions |
| Residual solvents | GC report with solvent list and limits | Separates intrinsic catechin risk from contamination questions |
| Heavy metals and pesticides | ICP-MS and pesticide screen | Needed to rule out confounding contaminant risk |
The 21 CFR 111.75 specification rule requires appropriate tests or examinations to verify identity, purity, strength, composition and contaminant limits. Blue Eye Biotech applies this logic to green tea extract release documents for B2B buyers.
Which EGCG dose levels should trigger regulatory review?
Answer: Regulatory review should trigger when a supplement approaches 300 mg EGCG/day, exceeds 100 mg EGCG/serving in food-like formats, uses capsule bolus delivery, directs fasting use, or approaches 800 mg EGCG/day. These values come from Health Canada and EFSA risk assessments, not marketing targets.
Different markets treat these values differently. Use them as internal QA decision points. Final label wording and serving size should be approved by the brand’s regulatory team for the destination country.
| Trigger point | Action | Authority basis |
|---|---|---|
| 100 mg EGCG/serving | Review serving count and food-like exposure | Health Canada supplemented-food serving concept |
| 300 mg EGCG/day | Start conservative daily-intake review | Health Canada RMDI for supplemented foods |
| 600 mg EGCG/day | Escalate to safety dossier review | Health Canada clinical-study NOAEL discussion |
| 600–800 mg EGCG/day | Review ALT/AST risk and dosage form | Health Canada noted enzyme activity elevation in capsule studies |
| ≥800 mg EGCG/day | Treat as major risk trigger | EFSA transaminase concern level |
“More women in the GTE group experienced an alanine aminotransferase (ALT) elevation compared with placebo group (n = 36, 6.7% vs. n = 4, 0.7%; P < 0.001).” Dostal A. M. et al., Food and Chemical Toxicology, 2015. PubMed Minnesota Green Tea Trial safety paper.
Why does fasting use change the green tea extract risk profile?
Answer: Fasting use matters because bolus green tea extract can increase catechin bioavailability, especially EGCG. USP and Health Canada both discuss higher risk under fasting or solid-dosage conditions. Product directions should avoid empty-stomach use when concentrated green tea extract is present.
Weight-management products are especially vulnerable because consumers may take them before meals or during dieting. This behavior is the opposite of the “take with food” risk-control approach discussed in USP’s review.
| Use pattern | Risk implication | Label-control language to review |
|---|---|---|
| Empty stomach capsule | Higher EGCG exposure concern | Do not take on an empty stomach |
| With meal | Lower acute bolus concern | Take with food |
| Multiple capsules per day | Cumulative EGCG can exceed design target | Do not exceed stated daily serving |
| Stacked fat-burner formulas | Combines EGCG, caffeine and other botanicals | Avoid use with other stimulant or green tea products |
The USP comprehensive review by Oketch-Rabah et al. associated hepatotoxicity case reports with EGCG intakes from 140 mg to about 1000 mg/day and emphasized substantial inter-individual variability. This is why Blue Eye Biotech recommends dose-based documentation rather than broad “green tea” assumptions.
How should caffeine be separated from EGCG in a LiverTox audit?
Answer: Caffeine should be audited separately because it affects stimulant exposure, blood pressure-sensitive consumers, pregnancy and lactation warnings, sleep complaints and stacked formulas. EGCG is the main liver-risk marker, while caffeine is a separate safety and label-positioning marker.
The NCCIH green tea safety page states that green tea contains caffeine and that green tea extract supplements can cause increased blood pressure. Caffeine disclosure becomes especially important when green tea extract appears with guarana, coffee bean, yerba mate or added caffeine.
| Audit question | Required data | Red flag |
|---|---|---|
| How much caffeine comes from green tea extract? | Batch-specific caffeine assay | Only “decaf” claim, no numerical limit |
| How much caffeine is in the whole formula? | Sum of all botanical and added caffeine sources | Guarana or coffee bean present without total caffeine calculation |
| Is the product positioned as stimulant-free? | Decaffeinated GTE certificate and caffeine limit | Non-decaf GTE in a “non-stimulant” formula |
| Does the consumer take it at night? | Serving time and caffeine exposure | Evening-use product with undisclosed caffeine |
Warning: Decaffeinated green tea extract lowers caffeine exposure, but it does not remove EGCG-driven liver-risk questions. QA still needs EGCG per serving, EGCG per day, catechin profile and take-with-food directions.
What supplier records reduce DILI attribution risk?
Answer: Supplier records reduce DILI attribution risk when they prove what the buyer received and how the batch differs from other green tea extracts. The key records are raw material identity, EGCG assay, total catechins, caffeine, contaminants, residual solvents, method traceability, retained samples and change-control notices.
If a liver complaint occurs, a vague COA cannot support an investigation. The brand needs exact batch data, ingredient lot linkage and a retained sample for retesting. This is not only regulatory hygiene; it protects both buyer and supplier from unsupported attribution.
| Record | Minimum content | Why it matters during DILI review |
|---|---|---|
| Batch COA | Lot number, test date, EGCG, caffeine, moisture and contaminants | Defines exposure from the actual batch |
| Raw chromatograms | EGCG, catechin profile and caffeine integration | Supports independent retest and method comparison |
| Reference standard traceability | Standard lot, purity, expiry and storage | Defends assay accuracy |
| Retained sample | Sealed reserve from production lot | Enables complaint retesting |
| Change-control notice | Extraction solvent, decaffeination, concentration or carrier change | Prevents hidden bioavailability or composition shifts |
What does Blue Eye Biotech's LiverTox Audit Support Program provide?
Answer: Blue Eye Biotech's LiverTox Audit Support Program helps supplement brands convert public safety signals into purchase specifications and batch files. The program supports EGCG 98%, standardized green tea extract, decaffeinated options and B2B documentation for importers, contract manufacturers and finished-product brands.
- EGCG dose documentation: batch-specific HPLC assay for EGCG 98% and standardized green tea extract grades.
- Caffeine and catechin profile: caffeine, EGCG, ECG, EGC, EC and GCG visibility for serving-size calculations.
- Decaf grade support: documentation for low-caffeine positioning when stimulant load is a formulation risk.
- Contaminant controls: residual solvents, heavy metals, pesticide screen and microbiological testing package.
- Retained-sample workflow: reserve sample support for complaint investigation and independent retesting.
- cGMP-ready supplier file: COA, method summary, questionnaire response and change-control communication.
What do brands ask most about LiverTox and EGCG?
Answer: Brands usually ask whether LiverTox means green tea extract should be avoided and whether caffeine is the main liver-risk factor. LiverTox does not ban green tea extract. It tells brands to quantify dose, dosage form, fasting use, susceptibility and batch composition before making label or purchase decisions.
FAQ 1: Does LiverTox mean all green tea extract is unsafe?
No. LiverTox says liver injury is rare relative to widespread use, but green tea extract is a well-established cause of clinically apparent liver injury. QA should control EGCG dose, form and warnings.
FAQ 2: Is caffeine the same as EGCG in a safety audit?
No. Caffeine affects stimulant exposure and label warnings, while EGCG is the main catechin marker in liver-risk reviews. Audit both separately by HPLC.
Author: Blue Eye Biotech Technical Team
Blue Eye Biotech is a Chinese manufacturer of pharmaceutical-grade botanical extracts, including EGCG 98%, Curcumin 95% and Marine Collagen Peptides for international B2B ingredient buyers.
